Literature DB >> 15013923

Macrolide antibiotics: current and future uses.

Marie-Thérèse Labro1.   

Abstract

After a long history of anti-infective therapeutic use, macrolide antibiotics have not yet given up all their secrets. Interest in their therapeutic potential in inflammatory diseases (possibly including non-infectious diseases) has generated abundant fundamental research and therapeutic trials worldwide. The main question regarding the future prospects of this class of drugs is whether some macrolides are beneficial in such settings because they modulate host inflammatory responses (and cellular targets) or rather because they eliminate a latent, unidentified pathogen which triggers chronic inflammation. However, no clearcut results have yet been obtained.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15013923     DOI: 10.1517/14656566.5.3.541

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  5 in total

1.  Short-term roxithromycin treatment attenuates airway inflammation via MAPK/NF-κB activation in a mouse model of allergic asthma.

Authors:  Xinxin Ci; Xiao Chu; Xue Xu; Hongyu Li; Xuming Deng
Journal:  Inflamm Res       Date:  2012-04-06       Impact factor: 4.575

2.  The macrolide roxithromycin impairs NADPH oxidase activation and alters translocation of its cytosolic components to the neutrophil membrane in vitro.

Authors:  Houria Abdelghaffar; Catherine Babin-Chevaye; Marie-Thérèse Labro
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

3.  [Systemic therapy of rosacea].

Authors:  M Schaller; K Belge
Journal:  Hautarzt       Date:  2013-07       Impact factor: 0.751

Review 4.  From Erythromycin to Azithromycin and New Potential Ribosome-Binding Antimicrobials.

Authors:  Dubravko Jelić; Roberto Antolović
Journal:  Antibiotics (Basel)       Date:  2016-09-01

Review 5.  Erythromycin: an alternative for the management of oral mucositis?

Authors:  D-S Teixeira; G-C Louzeiro; M-A Figueiredo; K Cherubini; F-G Salum
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2022-09-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.